From a pharmacological safety perspective, the adverse effect profile of retatrutide based on Phase 1 and Phase 2 clinical trial data (including the NEJM 2023 Phase 2 trial) includes: Gastrointestinal effects: Nausea, vomiting, diarrhoea, and constipation (the most commonly reported side effects in trial participants) Injection site reactions: Redness, swelling, or discomfort at the injection site Cardiovascular effects: Increases in heart rate have been observed in trial participants [21] [22] Hypoglycaemia: Particularly relevant in individuals with diabetes or those taking insulin, sulfonylureas, or other glucose-lowering agents Potential thyroid effects: GLP-1 receptor agonists have been associated with thyroid C-cell changes in rodent studies
Intestinal fungi contribute to development of alcoholic liver disease
Sodium Hyaluronate: Deeply hydrates the skin
Acetyl-L-carnitine should be avoided by people with seizure disorders, as it may increase seizure frequency
Ligament Repair Findings Ligament studies suggest BPC-157 may: Improve ligament-to-bone integration Reduce healing time after surgical injury Enhance collagen maturation These effects are especially relevant for ligament reconstructions and chronic ligament laxity
